Worldwide investors commit millions of dollars to drug companies, hoping that a new drug will become a blockbuster. However, before committing, investors should consider a thorough scientific due diligence to reduce risk. On May 7th, Actinogen, a small-cap Australian company, announced that their phase-2 trial of Xanamem showed no cognitive improvement in Alzheimer's disease (AD)patients. Below is an analysis of the scientific rationale for Xanamem’s trial, which identifies issues that could explain the recent and future failures of Actinogen’s Xanamem.
Xanamem is a small-molecule inhibitor of the 11?-hydroxysteroid dehydrogenase type 1 ((11?-HSD1)). Xanamem